The Isoxazole Ring and Its N‐Oxide: A Privileged Core Structure in Neuropsychiatric Therapeutics
- 2 March 2017
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 12 (6), 408-419
- https://doi.org/10.1002/cmdc.201700023
Abstract
Mental disorders are neuropsychiatric conditions that are marked by unusual or irregular thinking, feelings, or behavior, and lead to distress and/or impaired functions. Major psychiatric conditions are depression, anxiety, and psychoses of various types. Their etiopathogeneses, of a primary or secondary origin, are associated with genetic and environmental factors. They are commonly treated with psychoactive drugs (also known as psychotropics), which target serotonin, dopamine, norepinephrine, glutamate, and nuclear receptors (NRs), including retinoic acid receptor-related orphan receptors (RORs) and other receptors in the central nervous system (CNS). Herein we present a diverse array of isoxazole derivatives, among which are some prominent marketed drugs. Some of the derivatives and forms, including N-oxides, are under either (pre)clinical evaluation or patent protection as new generation of psychotropics, and a few have effective blood–brain barrier (BBB) permeability. Various drug-like isoxazol(in)es and their structural features and efficiency, modified through scaffold hopping, are described and discussed in the context of treating neuropsychiatric conditions.Keywords
This publication has 101 references indexed in Scilit:
- DIAGNOSTIC OVERLAP OF GENERALIZED ANXIETY DISORDER AND MAJOR DEPRESSIVE DISORDER IN A PRIMARY CARE SAMPLEDepression and Anxiety, 2012
- Classification of scaffold-hopping approachesDrug Discovery Today, 2012
- Furoxans (1,2,5-Oxadiazole-N-Oxides) as Novel NO Mimetic Neuroprotective and Procognitive AgentsJournal of Medicinal Chemistry, 2012
- Identification of Novel α4β2-Nicotinic Acetylcholine Receptor (nAChR) Agonists Based on an Isoxazole Ether Scaffold that Demonstrate Antidepressant-like ActivityJournal of Medicinal Chemistry, 2011
- Discovery of Isoxazole Analogues of Sazetidine-A as Selective α4β2-Nicotinic Acetylcholine Receptor Partial Agonists for the Treatment of DepressionJournal of Medicinal Chemistry, 2011
- Recent Advances in the Design and Development of Novel Negative Allosteric Modulators of mGlu5ACS Chemical Neuroscience, 2011
- Discovery, Synthesis, and Biological Evaluation of a Novel Group of Selective Inhibitors of Filoviral EntryJournal of Medicinal Chemistry, 2011
- A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in SchizophreniaNeuropsychopharmacology, 2010
- Prototypic GABAA Receptor Agonist Muscimol Acts Preferentially Through Forebrain High-Affinity Binding SitesNeuropsychopharmacology, 2009
- How many drug targets are there?Nature Reviews Drug Discovery, 2006